Charles Schwab
FLNA

Charles Schwab’s Filana Therapeutics FLNA Stock Holding History

Charles Schwab’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.2K Sell
25,561
-437
-2% -$900 ﹤0.01% 3425
2025
Q4 		$51.5K Sell
25,998
-51
-0.2% -$163 ﹤0.01% 3424
2025
Q3 		$75.8K Sell
26,049
-239,241
-90% -$550K ﹤0.01% 3405
2025
Q2 		$480K Sell
265,290
-95,963
-27% -$171K ﹤0.01% 3153
2025
Q1 		$542K Buy
361,253
+41,511
+13% +$105K ﹤0.01% 3052
2024
Q4 		$755K Sell
319,742
-42,055
-12% -$739K ﹤0.01% 3005
2024
Q3 		$10.6M Buy
361,797
+10,429
+3% +$240K ﹤0.01% 1995
2024
Q2 		$4.34M Buy
351,368
+34,977
+11% +$737K ﹤0.01% 2414
2024
Q1 		$6.42M Buy
316,391
+7,555
+2% +$174K ﹤0.01% 2195
2023
Q4 		$6.95M Buy
308,836
+4,115
+1% +$86.9K ﹤0.01% 2172
2023
Q3 		$5.07M Buy
304,721
+9,314
+3% +$185K ﹤0.01% 2258
2023
Q2 		$7.24M Buy
295,407
+4,591
+2% +$111K ﹤0.01% 2063
2023
Q1 		$7.01M Buy
290,816
+10,705
+4% +$297K ﹤0.01% 2048
2022
Q4 		$8.27M Buy
280,111
+5,173
+2% +$186K ﹤0.01% 1970
2022
Q3 		$11.5M Buy
274,938
+7,327
+3% +$198K ﹤0.01% 1758
2022
Q2 		$7.53M Sell
267,611
-6,351
-2% -$160K ﹤0.01% 1988
2022
Q1 		$10.2M Buy
273,962
+6,462
+2% +$274K ﹤0.01% 1946
2021
Q4 		$11.7M Buy
267,500
+5,209
+2% +$273K ﹤0.01% 1925
2021
Q3 		$16.3M Buy
262,291
+167,214
+176% +$14M 0.01% 1733
2021
Q2 		$8.12M Buy
95,077
+12,041
+15% +$645K ﹤0.01% 2110
2021
Q1 		$3.73M Buy
83,036
+5,853
+8% +$230K ﹤0.01% 2436
2020
Q4 		$527K Buy
77,183
+20,246
+36% +$181K ﹤0.01% 2973
2020
Q3 		$656K Buy
56,937
+7,000
+14% +$31.6K ﹤0.01% 2804
2020
Q2 		$154K Buy
+49,937
New +$226K ﹤0.01% 3203
2016
Q4 		– Sell
-2,657
Closed -$19K – 3077
2016
Q3 		$19K Hold
2,657
– – ﹤0.01% 3035
2016
Q2 		$41K Hold
2,657
– – ﹤0.01% 3081
2016
Q1 		$42K Hold
2,657
– – ﹤0.01% 3032
2015
Q4 		$33K Hold
2,657
– – ﹤0.01% 3080
2015
Q3 		$35K Hold
2,657
– – ﹤0.01% 3074
2015
Q2 		$33K Sell
2,657
-7,972
-75% -$109K ﹤0.01% 3077
2015
Q1 		$141K Hold
10,629
– – ﹤0.01% 3001
2014
Q4 		$152K Hold
10,629
– – ﹤0.01% 3024
2014
Q3 		$291K Hold
10,629
– – ﹤0.01% 2813
2014
Q2 		$428K Buy
10,629
+7,972
+300% +$295K ﹤0.01% 2694
2014
Q1 		$103K Hold
2,657
– – ﹤0.01% 3041
2013
Q4 		$91K Hold
2,657
– – ﹤0.01% 3063
2013
Q3 		$56K Hold
2,657
– – ﹤0.01% 3049
2013
Q2 		$41K Buy
+2,657
New +$56.2K ﹤0.01% 3037

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Charles Schwab's FLNA Position: Q1 2026 in Review

Charles Schwab reduced its Filana Therapeutics (FLNA) stake by 1.7% in Q1 2026, selling an estimated $900 and leaving 25,561 shares worth $43.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3425.

Charles Schwab first reported a position in FLNA in Q2 2013 and has held it in 38 quarters since. The position peaked at $16.3M in Q3 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Charles Schwab held 25,561 shares of Filana Therapeutics worth $43.2K as of Q1 2026.
  • Charles Schwab sold 437 Filana Therapeutics shares in Q1 2026, an estimated $900.
  • Filana Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3425 holding.
  • Charles Schwab first reported a position in Filana Therapeutics in Q2 2013 and has held it in 38 quarters since.
  • Charles Schwab's Filana Therapeutics position peaked at $16.3M in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.